The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01X | Other antineoplastic agents | |
4
|
L01XX | Other antineoplastic agents | |
5
|
L01XX80 |
| Active Ingredient |
|---|
|
Imetelstat is an oligonucleotide telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), which prevents telomere binding. Telomerase activity and human telomerase reverse transcriptase (hTERT) RNA expression are known to be significantly increased in MDS and malignant stem and progenitor cells. Imetelstat treatment leads to reduction of telomere length, inhibition of malignant stem and progenitor cell proliferation and induction of apoptotic cell death leading to reduction of malignant clones. |
| Document | Type | Information Source | |
|---|---|---|---|
| RYTELO Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| RYTELO Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |